CDCosima Drewes

Cosima Drewes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cosima Drewes has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PLCG2 Exon-Skipped Variants: Insights into Their Potential Role in Chronic Lymphocytic Leukemia

    by Jialei Qi, Wen Li, Rashmi Priyadharshini Dheenadayalan, Deyan Yordanov Yosifov, Cosima Drewes, Martin Wist, Marcel Wieczorek, Vera Schmid, Elias Hobeika, Xiang Gao, et al.

    Bruton tyrosine kinase inhibitors (BTKi) are successful in treatment of chronic lymphocytic leukemia (CLL), yet acquired resistance remains a challenge. In our study, REC-1 cells that acquired resistance to BTKi tirabrutinib by long-term treatment gained a splice-site mutation (SSM) c.2236-1G>T in PLCG2. Notably, a deletion spanning c.2236-23_2238 at the same splice site (SSD) was identified in CLL from a patient who had disease progression during ibrutinib therapy. These alterations resulted in the exon-skipped variant, ∆21, which exhibited enhanced phospholipase activity. PLCG2 SSM REC-1 exhibited increased anti-IgM-mediated calcium flux and resistance to BTK inhibition but retained sensitivity to PLCγ inhibitors. By analyzing additional primary CLL samples, we identified widespread expression of two additional exon-skipped variants, ∆22 and ∆20-22, independent of PLCG2 genetic alterations. The active ∆20-22, which is also described in PLCG2-associated immune dysregulation (PLAID), was predominantly present in CLL compared to healthy donor samples. Expression analysis in CLL cells isolated from patients before and after targeted treatments revealed a decrease in expression of ∆20-22 post-venetoclax (p = 0.02)while no change in expression was observed after ibrutinib treatment, indicating that these variants may persist in the presence of ibrutinib but might be lost in the absence of drug selection pressure. Our study reveals novel PLCG2 splice-site alterations and exon-skipped variants beyond the classical BTK or PLCG2 mutations, to have a potential role in BTKi resistance and inform treatment selection.

  • Open Access

    Chronic lymphocytic leukemia with IGH :: BCL3 ‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape

    by Cosima Drewes, Cristina López, Juan Emilio Martinez‐Manjón, Nnamdi Okeke, Billy Jebaraj, Susanne Bens, Björn Brändl, Martin J. S. Dyer, Barbara Eichhorst, Anja Fischer, et al.

    Approximately 1% of chronic lymphocytic leukemia (CLL) cases harbor a translocation juxtaposing the immunoglobulin heavy chain ( IGH ) and B‐cell lymphoma 3 ( BCL3 ) loci. Aiming at comprehensive molecular characterization of IGH :: BCL3‐ positive B‐cell neoplasms, we here investigated samples from 84 patients using fluorescence in situ hybridization (FISH), whole‐genome and targeted sequencing, and DNA methylation analyses. Junctional sequences obtained in 27 patients showed breakpoints upstream of BCL3 in all CLL cases. IGH breaks were presumably driven by aberrant class‐switch recombination in 26/27 cases, frequently involving IGHA (12/26). Notably, 95% (78/82) of patients carried an unmutated IGHV with significant CLL stereotype subset #8 enrichment. Trisomy 12 (61%, 51/83) and mutations affecting NOTCH1 (32%, 25/79), BRAF (14%, 11/79), and FBXW7 (14%, 11/79) were frequent aberrations. DNA methylation analysis assigned 77% (51/66) of patients with IGH :: BCL3‐ translocation with at least 60% tumor cell content to the naive B‐cell‐like group but unraveled a distinct and during follow‐up stable signature resembling in part plasma cell‐like epigenetic features. A binary DNA methylation classifier using 20 CpGs could distinguish IGH :: BCL3 ‐translocated CLL samples from other CLL subtypes. In an efficacy cohort of 3832 previously untreated patients from GCLLSG trials, IGH::BCL3 was associated with shorter progression‐free survival (PFS) and overall survival (OS) in 28 patients when treated with chemoimmunotherapy, but not in those receiving venetoclax. Our findings highlight the genetic and epigenetic homogeneity of IGH :: BCL3 ‐translocated CLL samples and their differences from other types of CLL, suggesting IGH :: BCL3 leukemic B‐cell neoplasms to be a biological distinct type within the spectrum of mature lymphatic leukemia/CLL.

  • Open Access

    The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia

    by Cosima Drewes, Cristina López, Nnamdi Okeke, Billy Jebaraj, Christoph Wiegreffe, Isabelle Kraus, Sina Hillebrecht, Amani Awada, Susanne Bens, Emil Chteinberg, et al.

    Activation of oncogenes by hijacking immunoglobulin gene loci ( IG ) enhancers via chromosomal translocation is a common pathogenetic mechanism in B-cell malignancies, affecting 5–10% of chronic lymphocytic leukemia (CLL). The oncogenic partners in many of these cases remain unidentified. Therefore, we conducted a comprehensive analysis of 144 CLL samples with IGH- translocation excluding IGH :: BCL2 , IGH :: CCND1 , IGH :: BCL3 and IGH :: MYC . By combining fluorescence in situ hybridization (FISH) with whole-genome, targeted sequencing, and RNA expression profiling, we identified 25 IG -translocation partners; 12 were previously unreported. Of 142 cases, 107 (75%) displayed an unmutated IGHV . Genetic profiling showed a heterogenous distribution of chromosomal aberrations and recurrently mutated genes across the groups. Of 41 informative cases, 32 (78%) exhibited breakpoints driven by aberrant class-switch recombination (CSR), with prominent involvement of IGHM (9/41) and IGHG3 (9/41). Three cases with unmutated IGHV carried a juxtaposition of the IGH locus 5’ to the intact NKX2.6 gene in chromosome 8p21.2 due to illegitimate VDJ recombination, associated with significant ectopic upregulation of NKX2.6 transcriptional expression (FDR < 0.001, logFC: 15). Similarly, METRNL , located at the telomere of chromosome 17q25, was identified as a translocation partner gene in four cases. Our findings expand the spectrum of the oncogenic translocation partners targeting IGH in CLL.

  • Cyclin D1 rearranged diffuse large B-cell lymphoma—an evolving concept

    by K. S. Kurz, A. Zamo, C. Drewes, E. Madej, C. Laurent, B. Burroni, M. Donzel, L. Xerri, L. Mescam, L. Plank, et al.

    Rearrangement of Cyclin D1 (CCND1-R) is the hallmark genetic lesion of mantle cell lymphoma (MCL). However, recently diffuse large B-cell lymphomas (DLBCL) have been described carrying a CCND1-R, often with additional rearrangements of BCL2, BCL6 and/or MYC raising the question if these are bona fide DLBCL or pleomorphic MCL. Protein expression and fluorescence in situ hybridisation (FISH) screening of 708 aggressive B-cell lymphomas failed to disclose CCND1-R, demonstrating the rarity of such cases. Fifteen large B-cell tumours, with CCND1-R were collected from different institutions and characterized by immunohistochemistry and for their molecular features. Three of 15 cases were CD5 positive, and all cases were negative for SOX11 but exhibited cyclin D1 staining and CCND1-R by FISH. In 10/15 cases IG could be determined as rearrangement partner by FISH or WGS with occurrence of both aberrant VDJ rearrangement and IGH class-switch recombination (CSR). Eight of 15 tumours had additional translocations involving MYC, BCL2, or BCL6. 8/12 evaluable cases showed significantly mutated IGHV genes and evidence of intraclonal variations in their rearranged IGHV genes. WES disclosed a mutational spectrum typical of DLBCL in 14/14 evaluable cases. We conclude that DLBCL CCND1-R do exist and that CCND1-R in DLBCL can occur without additional translocations.